


## Vemtoberant

<b>Cat. No.:</b>	HY-148804		
<b>CAS No.:</b>	2169905-68-2		
<b>Molecular Formula:</b>	C <sub>29</sub> H <sub>37</sub> N <sub>3</sub> O <sub>8</sub> S <sub>2</sub>		
<b>Molecular Weight:</b>	619.75		
<b>Target:</b>	Adrenergic Receptor		
<b>Pathway:</b>	GPCR/G Protein; Neuronal Signaling		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 250 mg/mL (403.39 mM; Need ultrasonic)

Concentration	Mass		
	1 mg	5 mg	10 mg
1 mM	1.6136 mL	8.0678 mL	16.1355 mL
5 mM	0.3227 mL	1.6136 mL	3.2271 mL
10 mM	0.1614 mL	0.8068 mL	1.6136 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

Vemtoberant is an  $\beta_3$  Adrenergic Receptor antagonist. Vemtoberant can be used for research of  $\beta_3$  adrenergic receptor-mediated disorder, such as, heart failure<sup>[1][2]</sup>.

### REFERENCES

- [1]. Tran Thuy-Anh, et al. Preparation of modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related thereto: World Intellectual Property Organization, WO2017214002. 2017-12-14.
- [2]. WHO Drug Information-World Health Organization (WHO).

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA